(Q37873719)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21556025%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

review article

1 reference

title

Bone metastasis in prostate cancer: emerging therapeutic strategies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21556025%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21556025%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

author name string

Matthew P Caley

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21556025%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Jonathan Waxman

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21556025%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

language of work or name

English

0 references

publication date

10 May 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21556025%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

31 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21556025%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21556025%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21556025%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

page(s)

357-368

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21556025%20AND%20SRC:MED&resulttype=core&format=json

Metastasis to bone: causes, consequences and therapeutic opportunities

31 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Drug resistance in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Skeletal remodeling in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Rho GTPases in osteoclasts: orchestrators of podosome arrangement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Src-dependent repression of ARF6 is required to maintain podosome-rich sealing zones in bone-digesting osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Vesicular trafficking in osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Synthesis and secretion of collagen by cells of connective tissue, bone, and dentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Exocytotic process as a novel model for mineralization by osteoblasts in vitro and in vivo determined by electron microscopic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Molecular mechanisms and treatment of bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Evolving Role of Bone Biomarkers in Castration-Resistant Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Bisphosphonates: mechanism of action and role in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Molecular mechanisms of action of bisphosphonates: current status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Cathepsin K mRNA and protein expression in prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

The adaptor protein Tks5/Fish is required for podosome formation and function, and for the protease-driven invasion of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Active Rho is localized to podosomes induced by oncogenic Src and is required for their assembly and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

ERK5 promotes Src-induced podosome formation by limiting Rho activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

TGF-beta induces formation of F-actin cores and matrix degradation in human breast cancer cells via distinct signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Lysosomal cathepsin B participates in the podosome-mediated extracellular matrix degradation and invasion via secreted lysosomes in v-Src fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Drug-induced morphea: report of a case induced by balicatib and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Cathepsin K inhibitors for osteoporosis and potential off-target effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Decreased c-Src expression enhances osteoblast differentiation and bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Transforming growth factor-beta1 to the bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Role of transforming growth factor beta in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Role of transforming growth factor-beta superfamily signaling pathways in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

A multigenic program mediating breast cancer metastasis to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-β receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Knockdown of the transforming growth factor-beta type III receptor impairs motility and invasion of metastatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

TGFbeta signalling: a complex web in cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Targeted radiotherapy of bone malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Treatment of painful bone metastases in hormone-refractory prostate cancer with zoledronic acid and samarium-153-ethylenediaminetetramethylphosphonic acid combined

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Bone-specific growth inhibition of prostate cancer metastasis by atrasentan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Role of endothelin-1 in osteoblastic bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Wnt10b increases postnatal bone formation by enhancing osteoblast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

The role of Wnts in bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Regulation of cell signalling by uPAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Three-dimensional type I collagen gel system for the study of osteoblastic metastases produced by metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Antitumoral activity and osteogenic potential of mesenchymal stem cells expressing the urokinase-type plasminogen antagonist amino-terminal fragment in a murine model of osteolytic tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

GPI-anchored uPAR requires Endo180 for rapid directional sensing during chemotaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Endo180 binds to the C-terminal region of type I collagen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Endosomes generate localized Rho-ROCK-MLC2-based contractile signals via Endo180 to promote adhesion disassembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Characterization of a novel member of the macrophage mannose receptor type C lectin family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Balancing selection of a frame-shift mutation in the MRC2 gene accounts for the outbreak of the Crooked Tail Syndrome in Belgian Blue Cattle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Complementary roles of intracellular and pericellular collagen degradation pathways in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

A role for fibrillar collagen deposition and the collagen internalization receptor endo180 in glioma invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

The collagen receptor Endo180 (CD280) Is expressed on basal-like breast tumor cells and promotes tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Endo180 expression with cofunctional partners MT1-MMP and uPAR-uPA is correlated with prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Osteoblast-derived factors induce an expression signature that identifies prostate cancer metastasis and hormonal progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Identification of an alternatively spliced variant of Ca2+-promoted Ras inactivator as a possible regulator of RANKL shedding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Early androgen deprivation for prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

The collagenolytic activity of cathepsin K is unique among mammalian proteinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Management of vertebral metastases in prostate cancer: a retrospective analysis in 119 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Proteolysis of human bone collagen by cathepsin K: characterization of the cleavage sites generating by cross-linked N-telopeptide neoepitope

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Novel actions of bisphosphonates in bone: Preservation of osteoblast and osteocyte viability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

TGF-beta type II receptor phosphorylates PTH receptor to integrate bone remodelling signalling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Prostate cancer cells promote osteoblastic bone metastases through Wnts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Induction in human osteoblastic cells (SaOS2) of the early response genes fos, jun, and myc by the amino terminal fragment (ATF) of urokinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Sequences outside the homeodomain of bicoid are required for protein-protein interaction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.67

The use of bisphosphonates in men with hormone-refractory prostate cancer: a systematic review of randomized trials.

31 March 2020

1 reference

12 December 2020

Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial

1 reference

12 December 2020

The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer

1 reference

12 December 2020

Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer

1 reference

12 December 2020

Loss of inhibition over master pathways of bone mass regulation results in osteosclerotic bone metastases in prostate cancer

1 reference

12 December 2020

Breast cancer-derived factors facilitate osteolytic bone metastasis.

1 reference

12 December 2020

Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo.

1 reference

12 December 2020

Three-dimensional type I collagen co-culture systems for the study of cell-cell interactions and treatment response in bone metastases

1 reference

12 December 2020

10.1038/NRCLINONC.2011.67

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21556025%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1 reference